Innova Captab (INNOVACAP) | Financial Analysis & Statements
Innova Captab Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
3.5B
Gross Profit
1.3B
37.21%
Operating Income
410.5M
11.68%
Net Income
310.2M
8.82%
EPS (Diluted)
₹5.42
Balance Sheet Metrics
Total Assets
15.8B
Total Liabilities
6.2B
Shareholders Equity
9.6B
Debt to Equity
0.65
Cash Flow Metrics
Operating Cash Flow
378.6M
Free Cash Flow
-908.6M
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Innova Captab Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 12.3B | 10.8B | 9.3B | 8.0B | 4.1B |
| Cost of Goods Sold | 8.4B | 7.5B | 7.0B | 6.3B | 3.1B |
| Gross Profit | 4.0B | 3.3B | 2.2B | 1.7B | 952.6M |
| Gross Margin % | 32.1% | 30.3% | 24.2% | 21.7% | 23.3% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 235.9M | 213.2M | 170.4M | 85.9M | 33.9M |
| Other Operating Expenses | 746.0M | 610.1M | 390.6M | 288.5M | 158.4M |
| Total Operating Expenses | 981.9M | 823.2M | 561.0M | 374.4M | 192.3M |
| Operating Income | 1.7B | 1.4B | 1.1B | 886.9M | 491.4M |
| Operating Margin % | 13.4% | 13.1% | 11.4% | 11.1% | 12.0% |
| Non-Operating Items | |||||
| Interest Income | 30.4M | 37.3M | 7.1M | 1.4M | 2.4M |
| Interest Expense | 22.4M | 212.0M | 189.4M | 53.0M | 35.9M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 1.7B | 1.3B | 918.0M | 857.2M | 463.4M |
| Income Tax | 427.6M | 351.8M | 238.4M | 217.7M | 118.4M |
| Effective Tax Rate % | 25.0% | 27.2% | 26.0% | 25.4% | 25.6% |
| Net Income | 1.3B | 943.4M | 679.5M | 639.5M | 345.0M |
| Net Margin % | 10.4% | 8.8% | 7.3% | 8.0% | 8.4% |
| Key Metrics | |||||
| EBITDA | 2.0B | 1.7B | 1.2B | 986.5M | 555.6M |
| EPS (Basic) | ₹22.41 | ₹18.66 | ₹11.87 | ₹11.18 | ₹6.03 |
| EPS (Diluted) | ₹22.41 | ₹18.66 | ₹11.87 | ₹11.18 | ₹6.03 |
| Basic Shares Outstanding | 57224929 | 50563901 | 57224929 | 57224929 | 57224929 |
| Diluted Shares Outstanding | 57224929 | 50563901 | 57224929 | 57224929 | 57224929 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Innova Captab Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 155.2M | 117.3M | 35.2M | 1.5M | 48.0M |
| Short-term Investments | 497.6M | 723.6M | 35.0M | 7.2M | 108.9M |
| Accounts Receivable | 3.3B | 2.9B | 2.7B | 2.1B | 1.4B |
| Inventory | 2.1B | 1.4B | 1.2B | 1.3B | 914.4M |
| Other Current Assets | 24.2M | 18.8M | 14.8M | 8.3M | 295.6M |
| Total Current Assets | 7.0B | 5.8B | 4.4B | 3.8B | 2.7B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 442.9M | 265.2M | 144.8M | 148.0M | 34.2M |
| Goodwill | 341.3M | 342.8M | 341.6M | 338.4M | 4.4M |
| Intangible Assets | 7.4M | 9.0M | 7.7M | 4.5M | 4.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 35.0M | 192.0M | 561.7M | - | - |
| Total Non-Current Assets | 8.8B | 7.4B | 2.6B | 2.0B | 991.5M |
| Total Assets | 15.8B | 13.2B | 7.0B | 5.8B | 3.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.0B | 1.8B | 1.6B | 1.4B | 1.1B |
| Short-term Debt | 932.2M | 345.8M | 1.0B | 1.3B | 391.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 48.9M | 25.4M | 20.1M | 11.2M | 69.0M |
| Total Current Liabilities | 3.5B | 2.7B | 2.8B | 2.9B | 2.2B |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.4B | 2.1B | 1.4B | 679.4M | 63.5M |
| Deferred Tax Liabilities | 131.9M | 48.4M | 39.2M | 20.6M | 19.3M |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 2.7B | 2.2B | 1.5B | 723.5M | 96.4M |
| Total Liabilities | 6.2B | 4.9B | 4.3B | 3.7B | 2.2B |
| Equity | |||||
| Common Stock | 572.2M | 572.2M | 480.0M | 120.0M | 120.0M |
| Retained Earnings | 4.5B | 3.2B | 2.3B | 2.0B | 1.3B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 9.6B | 8.3B | 2.8B | 2.1B | 1.4B |
| Key Metrics | |||||
| Total Debt | 3.4B | 2.5B | 2.4B | 2.0B | 455.0M |
| Working Capital | 3.5B | 3.1B | 1.6B | 845.3M | 553.1M |
Balance Sheet Composition
Innova Captab Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.7B | 1.3B | 918.0M | 857.2M | 463.4M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -1.4B | 960.0K | -455.2M | -343.3M | -113.8M |
| Operating Cash Flow | 282.9M | 1.5B | 632.9M | 586.4M | 386.2M |
| Investing Activities | |||||
| Capital Expenditures | -1.7B | -2.9B | -782.5M | -798.0M | -184.5M |
| Acquisitions | 0 | -1.6B | 0 | -1.1B | 50.0K |
| Investment Purchases | -966.6M | -494.4M | -153.1M | -21.5M | -13.0M |
| Investment Sales | 1.1B | 0 | 22.5M | 71.0M | 0 |
| Investing Cash Flow | -1.6B | -5.0B | -913.1M | -1.9B | -197.4M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 637.0M | 1.7B | 495.1M | 1.1B | 0 |
| Debt Repayment | -114.0M | -1.2B | -593.4M | -390.6M | -56.1M |
| Financing Cash Flow | 941.0M | 2.8B | 158.8M | 1.3B | -157.1M |
| Free Cash Flow | -1.1B | -1.4B | -118.7M | -209.8M | 228.3M |
| Net Change in Cash | -331.0M | -767.4M | -121.5M | 6.6M | 31.7M |
Cash Flow Trend
Innova Captab Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
31.20
Forward P/E
21.90
Price to Book
4.05
Price to Sales
2.76
PEG Ratio
1.33
Profitability Ratios
Profit Margin
8.85%
Operating Margin
12.88%
Return on Equity
13.37%
Return on Assets
8.12%
Financial Health
Current Ratio
1.97
Debt to Equity
32.95
Beta
-0.33
Per Share Data
EPS (TTM)
₹23.16
Book Value per Share
₹178.28
Revenue per Share
₹261.54
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| INNOVACAP | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
| Aarti Drugs | 34.0B | 16.37 | 2.43 | 12.28% | 8.03% | 39.05 |
Financial data is updated regularly. All figures are in the company's reporting currency.





